Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. Goetz MP, et al. Among authors: mcgovern rm. Invest New Drugs. 2013 Dec;31(6):1559-67. doi: 10.1007/s10637-013-0034-9. Epub 2013 Oct 10. Invest New Drugs. 2013. PMID: 24114122 Free PMC article. Clinical Trial.
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. Dickson MA, et al. Among authors: mcgovern rm. Invest New Drugs. 2011 Oct;29(5):1004-12. doi: 10.1007/s10637-010-9447-x. Epub 2010 May 12. Invest New Drugs. 2011. PMID: 20461440 Free PMC article. Clinical Trial.
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. Schelman WR, et al. Among authors: mcgovern rm. Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10. Invest New Drugs. 2013. PMID: 24114121 Free PMC article. Clinical Trial.
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. Deming DA, et al. Among authors: mcgovern rm. Invest New Drugs. 2014 Apr;32(2):323-9. doi: 10.1007/s10637-013-0035-8. Epub 2013 Oct 10. Invest New Drugs. 2014. PMID: 24114123 Free PMC article. Clinical Trial.
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Jaeckle KA, et al. Among authors: mcgovern rm. J Neurooncol. 2010 Aug;99(1):73-80. doi: 10.1007/s11060-009-0103-2. Epub 2010 Jan 9. J Neurooncol. 2010. PMID: 20063115 Free PMC article. Clinical Trial.
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. Hummel TR, et al. Among authors: mcgovern rm. Pediatr Blood Cancer. 2013 Sep;60(9):1452-7. doi: 10.1002/pbc.24541. Epub 2013 Mar 28. Pediatr Blood Cancer. 2013. PMID: 23554030 Free PMC article. Clinical Trial.
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. Goetz MP, et al. Among authors: mcgovern rm. J Clin Oncol. 2017 Oct 20;35(30):3391-3400. doi: 10.1200/JCO.2017.73.3246. Epub 2017 Aug 30. J Clin Oncol. 2017. PMID: 28854070 Free PMC article. Clinical Trial.
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors.
Koubek EJ, Ralya AT, Larson TR, McGovern RM, Buhrow SA, Covey JM, Adjei AA, Takebe N, Ames MM, Goetz MP, Reid JM. Koubek EJ, et al. Among authors: mcgovern rm. J Clin Pharmacol. 2022 Sep;62(9):1121-1131. doi: 10.1002/jcph.2053. Epub 2022 Apr 19. J Clin Pharmacol. 2022. PMID: 35358345 Free PMC article.
Comparative bioavailability of sulindac in capsule and tablet formulations.
Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ; Cancer Prevention Network. Reid JM, et al. Among authors: mcgovern rm. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):674-9. doi: 10.1158/1055-9965.EPI-07-2510. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18349286 Free PMC article.
58 results